Coats disease associated with muscular dystrophy treated with ranibizumab

Eye

Volumn 24, Issue 7, 2010, Pages 1295-1296

  Diago, T ^a   Valls, B ^a   Pulido, J S ^b  

^a Hospital of Sagunto   (Spain)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ADULT; CASE REPORT; DISEASE ASSOCIATION; EXUDATIVE RETINITIS; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FLUORESCENCE ANGIOGRAPHY; HUMAN; LABORATORY TEST; LASER COAGULATION; LETTER; MALE; OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY;

EID: 77954738988     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.336     Document Type: Letter

References (5)

1. Retina and Vitreous. Basic and Clinical Science Course Section 12. American Academy of Ophthalmology: Singapore, 2007
2. Venkatesh P,Mandal S, Garg S.Management of Coats disease with bevacizumab in 2 patients. Can J Ophthalmol 2008; 43: 245-246.
3. Shields CL, Zahler J, Falk N, Furuta M, Eagle Jr RC, Espinosa LE et al. Neovascular glaucoma from advanced Coats disease as the initial manifestation of facioscapulohumeral dystrophy in a 2-year-old child. Arch Ophthalmol 2007; 125(6): 840-842.
4. Brouwer OF, Padberg GW, Ruys CJ, Brand R, de Laat JA, Grote JJ. Hearing loss in facioscapulohumeral muscular dystrophy. Neurology 1991; 41: 1878-1881.
5. Fitzsimons RB, Gurwin EB, Bird AC. Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy: a general association with genetic and therapeutic implications. Brain 1987; 110: 631-648.